首页 > 最新文献

Japanese journal of clinical oncology最新文献

英文 中文
Assessing alimentary tract radiation in liver cancer treatment with proton beam therapy: a PET/CT imaging study. 评估肝癌质子束治疗中的消化道辐射:PET/CT 成像研究。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae085
Sachika Shiraishi, Masashi Yamanaka, Shintaro Shiba, Koichi Tokuuye

Background: Proton beams deposit energy along their path, abruptly stopping and generating various radioactive particles, including positrons, along their trajectory. In comparison with traditional proton beam therapy, scanning proton beam therapy is effective in delivering proton beams to irregularly shaped tumors, reducing excessive radiation exposure to the alimentary tract during the treatment of liver cancer.

Methods: In this study, we utilized positron emission tomography/computed tomography (PET/CT) imaging to assess the total amount of radiation to the alimentary tract during liver cancer treatment with proton beam therapy, involving the administration of complex irradiation in 13 patients.

Results: This approach resulted in the prevention of excess radiation. The planned radiation restraint doses for the colon exhibited a significant correlation with the PET values of the colon (correlation coefficient 0.8384, P = .0003). Likewise, the scheduled radiation restraint doses for the gastroduodenum were correlated with the PET values of the gastroduodenum (correlation coefficient 0.5397, P = .0569).

Conclusions: PET/CT conducted after proton beam therapy is useful for evaluating excess radiation in the alimentary tract. Proton beam therapy in liver cancer, assessed via PET/CT, effectively reduced alimentary tract radiation, which is vital for optimizing treatments and preventing excess exposure.

背景:质子束沿其轨迹沉积能量,突然停止并产生各种放射性粒子,包括正电子。与传统的质子束疗法相比,扫描质子束疗法能有效地将质子束投射到形状不规则的肿瘤上,减少肝癌治疗过程中消化道受到的过量辐射:在这项研究中,我们利用正电子发射断层扫描/计算机断层扫描(PET/CT)成像技术评估了13名患者在接受质子束疗法治疗肝癌期间消化道所受的辐射总量,其中包括复合照射:结果:这一方法避免了过量辐射。结肠的计划限制辐射剂量与结肠 PET 值有显著相关性(相关系数 0.8384,P = 0.0003)。同样,胃十二指肠的计划辐射抑制剂量与胃十二指肠的 PET 值也有相关性(相关系数 0.5397,P = .0569):结论:质子束治疗后进行的 PET/CT 可用于评估消化道的过量辐射。通过 PET/CT 评估肝癌质子束治疗可有效减少消化道辐射,这对优化治疗和防止辐射过量至关重要。
{"title":"Assessing alimentary tract radiation in liver cancer treatment with proton beam therapy: a PET/CT imaging study.","authors":"Sachika Shiraishi, Masashi Yamanaka, Shintaro Shiba, Koichi Tokuuye","doi":"10.1093/jjco/hyae085","DOIUrl":"10.1093/jjco/hyae085","url":null,"abstract":"<p><strong>Background: </strong>Proton beams deposit energy along their path, abruptly stopping and generating various radioactive particles, including positrons, along their trajectory. In comparison with traditional proton beam therapy, scanning proton beam therapy is effective in delivering proton beams to irregularly shaped tumors, reducing excessive radiation exposure to the alimentary tract during the treatment of liver cancer.</p><p><strong>Methods: </strong>In this study, we utilized positron emission tomography/computed tomography (PET/CT) imaging to assess the total amount of radiation to the alimentary tract during liver cancer treatment with proton beam therapy, involving the administration of complex irradiation in 13 patients.</p><p><strong>Results: </strong>This approach resulted in the prevention of excess radiation. The planned radiation restraint doses for the colon exhibited a significant correlation with the PET values of the colon (correlation coefficient 0.8384, P = .0003). Likewise, the scheduled radiation restraint doses for the gastroduodenum were correlated with the PET values of the gastroduodenum (correlation coefficient 0.5397, P = .0569).</p><p><strong>Conclusions: </strong>PET/CT conducted after proton beam therapy is useful for evaluating excess radiation in the alimentary tract. Proton beam therapy in liver cancer, assessed via PET/CT, effectively reduced alimentary tract radiation, which is vital for optimizing treatments and preventing excess exposure.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnosis of glioma recurrence using 18F-FAPI-04 and 18F-PSMA-1007 PET/CT. 使用 18F-FAPI-04 和 18F-PSMA-1007 PET/CT 诊断胶质瘤复发。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae087
Jingyu Fu, Daiyun Peng, Ying Zhang, Jiangyan Liu
{"title":"Diagnosis of glioma recurrence using 18F-FAPI-04 and 18F-PSMA-1007 PET/CT.","authors":"Jingyu Fu, Daiyun Peng, Ying Zhang, Jiangyan Liu","doi":"10.1093/jjco/hyae087","DOIUrl":"10.1093/jjco/hyae087","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141498081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discontinuation and non-publication of randomized controlled trials on cervical cancer or precancer. 终止和不公布宫颈癌或癌前病变随机对照试验。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae096
Dongfang Lu, Xiaolin Chen, Yanmin Mu, Lingxiao Kong, Ling Zhang, Juan Li

Background: Research waste is a considerable problem in clinical trials, with nonpublication being a significant contributor. We aimed to determine the prevalence of discontinuation and nonpublication of randomized controlled trials (RCTs) on cervical cancer or precancer.

Methods: We searched ClinicalTrials.gov for registered RCTs investigating cervical cancer or precancer that started between January 2000 and December 2020. The primary and secondary outcomes were trial nonpublication and premature discontinuation, respectively. Publication status was determined by systematic searches of peer-reviewed journals using the PubMed and Scopus databases.

Results: A total of 113 RCTs met the inclusion criteria. Among the 85 trials completed before December 2020, 44 (51.8%) were prematurely discontinued and 40 (47.1%) were unpublished. A single-center design (61.4% vs. 34.1%, P = .012) and lack of external funding (59.1% vs. 36.6%, P = .038) were significantly associated with trial discontinuation. Large-scale (target sample size >400; 46.7% vs. 17.5%, P = .004) and externally funded trials (66.7% vs. 35.0%, P = .004) were more likely to be published. Multivariate logistic analysis revealed that a large sample size [odd ratio (OR): 4.125, 95% confidence interval (CI): 1.511-11.259, P = .006] and presence of external funding (OR: 3.714, 95% CI: 1.513-9.117, P = .004) were independent positive factors for trial publication.

Conclusion: A significant proportion of RCTs related to cervical cancer or precancer were discontinued early or remain unpublished, resulting in a waste of research resources.

背景:在临床试验中,研究浪费是一个相当大的问题,而未公开是其中一个重要原因。我们旨在确定有关宫颈癌或癌前病变的随机对照试验(RCT)终止和未公开的普遍程度:我们在 ClinicalTrials.gov 上搜索了 2000 年 1 月至 2020 年 12 月间开始的研究宫颈癌或癌前病变的注册 RCT。主要和次要结果分别为试验未发表和过早终止。通过使用 PubMed 和 Scopus 数据库对同行评审期刊进行系统检索来确定发表情况:共有 113 项研究性试验符合纳入标准。在2020年12月之前完成的85项试验中,有44项(51.8%)提前终止,40项(47.1%)未发表。单中心设计(61.4% vs. 34.1%,P = .012)和缺乏外部资助(59.1% vs. 36.6%,P = .038)与试验中止有显著相关性。大规模试验(目标样本量大于400;46.7% vs. 17.5%,P = .004)和外部资助试验(66.7% vs. 35.0%,P = .004)更有可能发表。多变量逻辑分析显示,样本量大[奇数比(OR):4.125,95% 置信区间(CI):1.511-11.259,P = .006]和有外部资助(OR:3.714,95% CI:1.513-9.117,P = .004)是试验发表的独立积极因素:结论:相当一部分与宫颈癌或癌前病变有关的研究性试验提前终止或仍未发表,造成了研究资源的浪费。
{"title":"Discontinuation and non-publication of randomized controlled trials on cervical cancer or precancer.","authors":"Dongfang Lu, Xiaolin Chen, Yanmin Mu, Lingxiao Kong, Ling Zhang, Juan Li","doi":"10.1093/jjco/hyae096","DOIUrl":"10.1093/jjco/hyae096","url":null,"abstract":"<p><strong>Background: </strong>Research waste is a considerable problem in clinical trials, with nonpublication being a significant contributor. We aimed to determine the prevalence of discontinuation and nonpublication of randomized controlled trials (RCTs) on cervical cancer or precancer.</p><p><strong>Methods: </strong>We searched ClinicalTrials.gov for registered RCTs investigating cervical cancer or precancer that started between January 2000 and December 2020. The primary and secondary outcomes were trial nonpublication and premature discontinuation, respectively. Publication status was determined by systematic searches of peer-reviewed journals using the PubMed and Scopus databases.</p><p><strong>Results: </strong>A total of 113 RCTs met the inclusion criteria. Among the 85 trials completed before December 2020, 44 (51.8%) were prematurely discontinued and 40 (47.1%) were unpublished. A single-center design (61.4% vs. 34.1%, P = .012) and lack of external funding (59.1% vs. 36.6%, P = .038) were significantly associated with trial discontinuation. Large-scale (target sample size >400; 46.7% vs. 17.5%, P = .004) and externally funded trials (66.7% vs. 35.0%, P = .004) were more likely to be published. Multivariate logistic analysis revealed that a large sample size [odd ratio (OR): 4.125, 95% confidence interval (CI): 1.511-11.259, P = .006] and presence of external funding (OR: 3.714, 95% CI: 1.513-9.117, P = .004) were independent positive factors for trial publication.</p><p><strong>Conclusion: </strong>A significant proportion of RCTs related to cervical cancer or precancer were discontinued early or remain unpublished, resulting in a waste of research resources.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A review of cutaneous apocrine carcinoma: epidemiology, diagnosis, prognosis, and treatment options. 皮肤腺分泌癌综述:流行病学、诊断、预后和治疗方案。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae103
Seiji Tsuruta, Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Naoya Yamazaki

Cutaneous apocrine carcinoma is a rare skin cancer arising from apocrine sweat glands. Disease-specific treatments are required for cutaneous adnexal carcinomas due to their heterogeneous treatment responsiveness. This review reports on the epidemiology, diagnosis, pathological features, surgical management, and use of systemic therapies for cutaneous apocrine carcinoma. Diagnosing cutaneous apocrine carcinoma requires presenting with distinctive pathological features and excluding metastatic adenocarcinomas, particularly breast cancer. Clinical findings are essential to exclude metastatic adenocarcinomas, and immunohistochemistry can be used as an adjunctive tool to rule out other diseases. Wide local excision is the standard treatment for resectable cutaneous apocrine carcinomas. Prophylactic lymphadenectomy should be considered as a treatment option given the high incidence of lymph node metastasis. Generally, cutaneous apocrine carcinomas are resistant to chemotherapy and radiation therapy; however, adjuvant radiotherapy is recommended for high-risk patients. Radiation or systemic therapy is administered to patients with distant metastases or recurrence. The systemic therapeutic options include cytotoxic chemotherapy, hormonal therapy, targeted therapy, and immune checkpoint inhibitors. Given the lack of data on clinical prognosis and standardized treatments, further studies are needed to improve our understanding of cutaneous apocrine carcinomas.

皮肤附属腺癌是一种罕见的皮肤癌,源于附属汗腺。由于皮肤附件癌的治疗反应不一,因此需要针对具体疾病的治疗方法。本综述报告了皮肤附属腺癌的流行病学、诊断、病理特征、手术治疗和系统疗法的使用。诊断皮肤腺分泌癌需要具备独特的病理特征,并排除转移性腺癌,尤其是乳腺癌。临床发现是排除转移性腺癌的关键,免疫组化可作为排除其他疾病的辅助工具。局部广泛切除术是可切除皮肤腺癌的标准治疗方法。鉴于淋巴结转移的高发率,预防性淋巴结切除术应被视为一种治疗选择。一般来说,皮肤腺癌对化疗和放疗有抵抗力,但建议对高危患者进行辅助放疗。有远处转移或复发的患者可接受放射治疗或全身治疗。全身治疗方案包括细胞毒化疗、激素治疗、靶向治疗和免疫检查点抑制剂。由于缺乏有关临床预后和标准化治疗的数据,我们需要开展进一步的研究,以加深对皮肤腺分泌癌的了解。
{"title":"A review of cutaneous apocrine carcinoma: epidemiology, diagnosis, prognosis, and treatment options.","authors":"Seiji Tsuruta, Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Naoya Yamazaki","doi":"10.1093/jjco/hyae103","DOIUrl":"10.1093/jjco/hyae103","url":null,"abstract":"<p><p>Cutaneous apocrine carcinoma is a rare skin cancer arising from apocrine sweat glands. Disease-specific treatments are required for cutaneous adnexal carcinomas due to their heterogeneous treatment responsiveness. This review reports on the epidemiology, diagnosis, pathological features, surgical management, and use of systemic therapies for cutaneous apocrine carcinoma. Diagnosing cutaneous apocrine carcinoma requires presenting with distinctive pathological features and excluding metastatic adenocarcinomas, particularly breast cancer. Clinical findings are essential to exclude metastatic adenocarcinomas, and immunohistochemistry can be used as an adjunctive tool to rule out other diseases. Wide local excision is the standard treatment for resectable cutaneous apocrine carcinomas. Prophylactic lymphadenectomy should be considered as a treatment option given the high incidence of lymph node metastasis. Generally, cutaneous apocrine carcinomas are resistant to chemotherapy and radiation therapy; however, adjuvant radiotherapy is recommended for high-risk patients. Radiation or systemic therapy is administered to patients with distant metastases or recurrence. The systemic therapeutic options include cytotoxic chemotherapy, hormonal therapy, targeted therapy, and immune checkpoint inhibitors. Given the lack of data on clinical prognosis and standardized treatments, further studies are needed to improve our understanding of cutaneous apocrine carcinomas.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141855513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Venous thromboembolism in patients undergoing surgery for lung cancer: a post hoc analysis of the Cancer-VTE Registry. 肺癌手术患者的静脉血栓栓塞症:对癌症-VTE登记处的事后分析。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae090
Riken Kawachi, Tetsuya Okano, Nobuyasu Awano, Masaru Matsumoto, Jun Hosokawa, Atsushi Takita, Mari S Oba, Hideo Kunitoh

The relationship between lung cancer surgery and venous thromboembolism (VTE) in Japan has not been elucidated. This was a post hoc analysis of the Cancer-VTE Registry. The 1057 patients who underwent surgery for lung cancer were divided into the surgery alone (SA) group (n = 598) and the surgery plus chemotherapy (SC) group (n = 459), and the 1-year incidences of VTE and cerebral ischemia were analyzed. In the SA and SC groups, composite VTE was observed in one (0.2%) and 15 (3.3%) patients, respectively, and cerebral ischemia was observed in eight (1.3%) and four (0.9%) patients, respectively. Lymph node metastasis was more common in patients with D-dimer >1.2 μg/ml (odds ratio: 1.781, P = .004). SA had a low risk of VTE but a high risk of cerebral ischemia. Chemotherapy increases the risk of VTE. The D-dimer level was related to VTE and advanced cancer.

日本尚未阐明肺癌手术与静脉血栓栓塞(VTE)之间的关系。这是对癌症-VTE 登记进行的一项事后分析。1057 名接受肺癌手术的患者被分为单纯手术(SA)组(598 人)和手术加化疗(SC)组(459 人),并分析了 VTE 和脑缺血的 1 年发病率。在SA组和SC组中,分别有1例(0.2%)和15例(3.3%)患者出现复合VTE,分别有8例(1.3%)和4例(0.9%)患者出现脑缺血。淋巴结转移在D-二聚体大于1.2 μg/ml的患者中更为常见(几率比:1.781,P = .004)。SA发生VTE的风险较低,但发生脑缺血的风险较高。化疗会增加 VTE 的风险。D-二聚体水平与 VTE 和晚期癌症有关。
{"title":"Venous thromboembolism in patients undergoing surgery for lung cancer: a post hoc analysis of the Cancer-VTE Registry.","authors":"Riken Kawachi, Tetsuya Okano, Nobuyasu Awano, Masaru Matsumoto, Jun Hosokawa, Atsushi Takita, Mari S Oba, Hideo Kunitoh","doi":"10.1093/jjco/hyae090","DOIUrl":"10.1093/jjco/hyae090","url":null,"abstract":"<p><p>The relationship between lung cancer surgery and venous thromboembolism (VTE) in Japan has not been elucidated. This was a post hoc analysis of the Cancer-VTE Registry. The 1057 patients who underwent surgery for lung cancer were divided into the surgery alone (SA) group (n = 598) and the surgery plus chemotherapy (SC) group (n = 459), and the 1-year incidences of VTE and cerebral ischemia were analyzed. In the SA and SC groups, composite VTE was observed in one (0.2%) and 15 (3.3%) patients, respectively, and cerebral ischemia was observed in eight (1.3%) and four (0.9%) patients, respectively. Lymph node metastasis was more common in patients with D-dimer >1.2 μg/ml (odds ratio: 1.781, P = .004). SA had a low risk of VTE but a high risk of cerebral ischemia. Chemotherapy increases the risk of VTE. The D-dimer level was related to VTE and advanced cancer.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11532618/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations between early changes in the neutrophil-to-lymphocyte ratio after radical nephroureterectomy and treatment outcomes. 根治性肾切除术后中性粒细胞与淋巴细胞比率的早期变化与治疗效果之间的关系。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae081
Shun Saito, Hidetsugu Takahashi, Yuji Yata, Shigeyoshi Takamizawa, Shuhei Hara, Keiichiro Miyajima, Kosuke Iwatani, Keiji Yasue, Hideomi Nishikawa, Toshihiro Yamamoto, Haruhisa Koide, Ibuki Sadakane, Mahito Atsuta, Keiichiro Mori, Yu Imai, Sotaro Kayano, Masaya Murakami, Kojiro Tashiro, Shunsuke Tsuzuki, Hiroki Yamada, Jun Miki, Fumihiko Urabe, Takahiro Kimura, On Behalf Of Jikei-Scrum Collaborative Group

Objectives: This study explored the impacts of peri-operative changes in the neutrophil-to-lymphocyte ratio (NLR) on the survival rate after radical nephroureterectomy.

Methods: This retrospective analysis included a multicentric cohort of patients diagnosed with upper tract urothelial carcinoma (UTUC) who had undergone radical nephroureterectomy from 2012 to 2021. We assessed the preoperative NLR, postoperative NLR, delta-NLR (difference between postoperative and preoperative NLRs), and NLR change (ratio of postoperative to preoperative NLR). Additionally, patients were categorized according to increases in their preoperative and/or postoperative NLRs. Associations of survival with peri-operative changes in the NLR were investigated using Cox multivariate regression models.

Results: A total of 488 patients were included in the study, with a median age of 73 years. Among the patients, 105 (21.5%) exhibited elevated preoperative and postoperative NLRs, 88 (18.0%) exhibited elevated preoperative NLR only, 53 (10.9%) exhibited elevated postoperative NLR only, and 242 (49.6%) exhibited normal NLRs. Multivariate analysis indicated significant negative correlations between both preoperative and postoperative increased NLRs and oncological outcomes, including nonurothelial tract recurrence-free survival and cancer-specific survival (hazard ratio [HR]: 1.65, P = 0.017; HR: 2.12, P = 0.014, respectively).

Conclusion: This is the first study to evaluate the association between peri-operative changes in the NLR and the outcomes of patients with UTUC who underwent radical nephroureterectomy. Patients with elevated NLRs at both time points experienced considerably worse outcomes. Further research should explore whether increases in the NLR during long-term follow-up could indicate impending disease recurrence.

研究目的本研究探讨了围手术期中性粒细胞与淋巴细胞比值(NLR)的变化对根治性肾切除术后存活率的影响:这项回顾性分析包括2012年至2021年期间接受根治性肾切除术的上尿路上皮癌(UTUC)患者的多中心队列。我们评估了术前 NLR、术后 NLR、δ-NLR(术后 NLR 与术前 NLR 之差)和 NLR 变化(术后 NLR 与术前 NLR 之比)。此外,根据患者术前和/或术后 NLR 的增加情况对其进行分类。采用 Cox 多元回归模型研究了生存率与围手术期 NLR 变化的关系:研究共纳入 488 名患者,中位年龄为 73 岁。其中,105 例(21.5%)患者术前和术后 NLR 均升高,88 例(18.0%)患者仅术前 NLR 升高,53 例(10.9%)患者仅术后 NLR 升高,242 例(49.6%)患者 NLR 正常。多变量分析表明,术前和术后 NLRs 升高与肿瘤预后,包括非尿道无复发生存率和癌症特异性生存率之间存在显著负相关(危险比 [HR]:1.65,P = 0.017;HR:2.12,P = 0.014,分别如此):这是第一项评估NLR围手术期变化与接受根治性肾切除术的UTUC患者预后之间关系的研究。在两个时间点上NLR均升高的患者的预后要差得多。进一步的研究应探讨长期随访期间NLR的升高是否预示着疾病即将复发。
{"title":"Associations between early changes in the neutrophil-to-lymphocyte ratio after radical nephroureterectomy and treatment outcomes.","authors":"Shun Saito, Hidetsugu Takahashi, Yuji Yata, Shigeyoshi Takamizawa, Shuhei Hara, Keiichiro Miyajima, Kosuke Iwatani, Keiji Yasue, Hideomi Nishikawa, Toshihiro Yamamoto, Haruhisa Koide, Ibuki Sadakane, Mahito Atsuta, Keiichiro Mori, Yu Imai, Sotaro Kayano, Masaya Murakami, Kojiro Tashiro, Shunsuke Tsuzuki, Hiroki Yamada, Jun Miki, Fumihiko Urabe, Takahiro Kimura, On Behalf Of Jikei-Scrum Collaborative Group","doi":"10.1093/jjco/hyae081","DOIUrl":"10.1093/jjco/hyae081","url":null,"abstract":"<p><strong>Objectives: </strong>This study explored the impacts of peri-operative changes in the neutrophil-to-lymphocyte ratio (NLR) on the survival rate after radical nephroureterectomy.</p><p><strong>Methods: </strong>This retrospective analysis included a multicentric cohort of patients diagnosed with upper tract urothelial carcinoma (UTUC) who had undergone radical nephroureterectomy from 2012 to 2021. We assessed the preoperative NLR, postoperative NLR, delta-NLR (difference between postoperative and preoperative NLRs), and NLR change (ratio of postoperative to preoperative NLR). Additionally, patients were categorized according to increases in their preoperative and/or postoperative NLRs. Associations of survival with peri-operative changes in the NLR were investigated using Cox multivariate regression models.</p><p><strong>Results: </strong>A total of 488 patients were included in the study, with a median age of 73 years. Among the patients, 105 (21.5%) exhibited elevated preoperative and postoperative NLRs, 88 (18.0%) exhibited elevated preoperative NLR only, 53 (10.9%) exhibited elevated postoperative NLR only, and 242 (49.6%) exhibited normal NLRs. Multivariate analysis indicated significant negative correlations between both preoperative and postoperative increased NLRs and oncological outcomes, including nonurothelial tract recurrence-free survival and cancer-specific survival (hazard ratio [HR]: 1.65, P = 0.017; HR: 2.12, P = 0.014, respectively).</p><p><strong>Conclusion: </strong>This is the first study to evaluate the association between peri-operative changes in the NLR and the outcomes of patients with UTUC who underwent radical nephroureterectomy. Patients with elevated NLRs at both time points experienced considerably worse outcomes. Further research should explore whether increases in the NLR during long-term follow-up could indicate impending disease recurrence.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141450523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE). 基于 S-1 的化放疗与/或不使用 nivolumab 治疗不可切除的局部晚期或边缘可切除胰腺癌的随机 III 期试验方案摘要:JCOG1908E(穿透)。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae084
Yusuke Sano, Masashi Kanai, Chigusa Morizane, Keita Sasaki, Michio Yoshimura, Yoshinori Ito, Junji Furuse, Masato Ozaka, Haruhiko Fukuda, Makoto Ueno

Pancreatic cancer remains a highly lethal disease with a 5-year survival proportion of <10%. Chemoradiotherapy is a treatment option for unresectable locally advanced (UR-LA) or borderline resectable (BR) pancreatic cancer, but its efficacy is not sufficient. Induction of the synergistic effect of irradiation and immune checkpoint inhibitors can be an attractive strategy. An open-label randomized phase III trial has been conducted since October 2020 to confirm the superiority of nivolumab plus S-1-based chemoradiotherapy over S-1-based chemoradiotherapy alone in patients with UR-LA or BR pancreatic cancer. A total of 216 patients will be enrolled in 14 institutions within 3.5 years. The primary endpoint of the safety run-in part is dose-limiting toxicity, and that of the phase III part is overall survival. This trial was registered at the Japan Registry of Clinical Trials as jRCT2080225361 (https://jrct.niph.go.jp/latest-detail/jRCT2080225361).

胰腺癌仍然是一种致死率极高的疾病,其 5 年生存率仅为
{"title":"Protocol digest of a randomized phase III trial comparing S-1-based chemoradiotherapy with/without nivolumab for unresectable locally advanced or borderline resectable pancreatic cancer: JCOG1908E (PENETRATE).","authors":"Yusuke Sano, Masashi Kanai, Chigusa Morizane, Keita Sasaki, Michio Yoshimura, Yoshinori Ito, Junji Furuse, Masato Ozaka, Haruhiko Fukuda, Makoto Ueno","doi":"10.1093/jjco/hyae084","DOIUrl":"10.1093/jjco/hyae084","url":null,"abstract":"<p><p>Pancreatic cancer remains a highly lethal disease with a 5-year survival proportion of <10%. Chemoradiotherapy is a treatment option for unresectable locally advanced (UR-LA) or borderline resectable (BR) pancreatic cancer, but its efficacy is not sufficient. Induction of the synergistic effect of irradiation and immune checkpoint inhibitors can be an attractive strategy. An open-label randomized phase III trial has been conducted since October 2020 to confirm the superiority of nivolumab plus S-1-based chemoradiotherapy over S-1-based chemoradiotherapy alone in patients with UR-LA or BR pancreatic cancer. A total of 216 patients will be enrolled in 14 institutions within 3.5 years. The primary endpoint of the safety run-in part is dose-limiting toxicity, and that of the phase III part is overall survival. This trial was registered at the Japan Registry of Clinical Trials as jRCT2080225361 (https://jrct.niph.go.jp/latest-detail/jRCT2080225361).</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467933","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Soft-tissue sarcoma in Japan: National Cancer Registry-based analysis from 2016 to 2019. 日本的软组织肉瘤:基于全国癌症登记处的 2016 至 2019 年分析。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae088
Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Hiroya Kondo, Eisuke Kobayashi, Yoko Katoh, Takahiro Higashi, Akira Kawai

Background: No previous reports have characterized national profiles of soft-tissue sarcoma overall. We examined the nationwide statistics for soft-tissue sarcoma in Japan using data from the population-based National Cancer Registry.

Methods: We identified 23 522 soft-tissue-sarcoma patients who were entered in the National Cancer Registry during 2016-19 using International Classification of Diseases-Oncology, Third Edition codes for cancer topography and morphology. We extracted data on patient demographics, tumor details (reason for diagnosis, tumor location, histology, extent of disease), hospital volume/type, treatment, and prognosis for each patient.

Results: Soft-tissue sarcoma showed a slight male preponderance. Approximately 5500-6000 new cases were diagnosed as soft-tissue sarcoma per year, with the age-adjusted incidence of soft-tissue sarcoma being 3.22/100000/year. The age distribution showed a single peak in the 70-79 age range, and sex-stratified data showed it was higher in men. The most common histologic subtype was liposarcoma. The most frequent tumor locations were the soft tissue and skin, followed by the retroperitoneum. Extent of disease was categorized as: "localized" (31.3%), "regional" (38.9%), or "distant" (10.5%). We found significant associations between overall survival and sex, age, tumor location, facility type, hospital volume, reason for diagnosis, extent of disease, and surgical treatment.

Conclusions: This is the first study to outline the epidemiology, clinical features, treatment, prognosis, and significant factors affecting prognosis of soft-tissue sarcoma in Japan using the National Cancer Registry. Documenting our data regarding elderly patients' outcomes is essential so other countries showing similar population-aging trends can learn from our experiences.

Level of evidence: Prognostic studies, Level III.

背景:以前没有任何报告描述过全国软组织肉瘤的总体情况。我们利用基于人口的全国癌症登记处的数据,研究了日本全国软组织肉瘤的统计数据:我们使用《国际疾病分类-肿瘤学》第三版的癌症地形学和形态学代码,确定了 23 522 名软组织肉瘤患者,这些患者在 2016-19 年期间被录入全国癌症登记处。我们提取了每位患者的人口统计学、肿瘤详情(诊断原因、肿瘤位置、组织学、病变范围)、住院量/类型、治疗和预后等数据:结果:软组织肉瘤患者中男性略占多数。每年约有 5500-6000 例新病例被诊断为软组织肉瘤,经年龄调整后的软组织肉瘤发病率为 3.22/100000/年。年龄分布显示,在 70-79 岁年龄段有一个发病高峰,性别分层数据显示男性发病率较高。最常见的组织学亚型是脂肪肉瘤。最常见的肿瘤部位是软组织和皮肤,其次是腹膜后。病变范围分为"局部"(31.3%)、"区域"(38.9%)或 "远处"(10.5%)。我们发现总生存率与性别、年龄、肿瘤位置、医疗机构类型、医院规模、诊断原因、疾病范围和手术治疗之间存在明显关联:这是首次利用全国癌症登记资料概述日本软组织肉瘤的流行病学、临床特征、治疗、预后以及影响预后的重要因素的研究。记录我们关于老年患者预后的数据非常重要,这样其他有类似人口老龄化趋势的国家就可以借鉴我们的经验:预后研究,III 级。
{"title":"Soft-tissue sarcoma in Japan: National Cancer Registry-based analysis from 2016 to 2019.","authors":"Koichi Ogura, Chigusa Morizane, Tomoyuki Satake, Shintaro Iwata, Yu Toda, Shudai Muramatsu, Toshiyuki Takemori, Hiroya Kondo, Eisuke Kobayashi, Yoko Katoh, Takahiro Higashi, Akira Kawai","doi":"10.1093/jjco/hyae088","DOIUrl":"10.1093/jjco/hyae088","url":null,"abstract":"<p><strong>Background: </strong>No previous reports have characterized national profiles of soft-tissue sarcoma overall. We examined the nationwide statistics for soft-tissue sarcoma in Japan using data from the population-based National Cancer Registry.</p><p><strong>Methods: </strong>We identified 23 522 soft-tissue-sarcoma patients who were entered in the National Cancer Registry during 2016-19 using International Classification of Diseases-Oncology, Third Edition codes for cancer topography and morphology. We extracted data on patient demographics, tumor details (reason for diagnosis, tumor location, histology, extent of disease), hospital volume/type, treatment, and prognosis for each patient.</p><p><strong>Results: </strong>Soft-tissue sarcoma showed a slight male preponderance. Approximately 5500-6000 new cases were diagnosed as soft-tissue sarcoma per year, with the age-adjusted incidence of soft-tissue sarcoma being 3.22/100000/year. The age distribution showed a single peak in the 70-79 age range, and sex-stratified data showed it was higher in men. The most common histologic subtype was liposarcoma. The most frequent tumor locations were the soft tissue and skin, followed by the retroperitoneum. Extent of disease was categorized as: \"localized\" (31.3%), \"regional\" (38.9%), or \"distant\" (10.5%). We found significant associations between overall survival and sex, age, tumor location, facility type, hospital volume, reason for diagnosis, extent of disease, and surgical treatment.</p><p><strong>Conclusions: </strong>This is the first study to outline the epidemiology, clinical features, treatment, prognosis, and significant factors affecting prognosis of soft-tissue sarcoma in Japan using the National Cancer Registry. Documenting our data regarding elderly patients' outcomes is essential so other countries showing similar population-aging trends can learn from our experiences.</p><p><strong>Level of evidence: </strong>Prognostic studies, Level III.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141544831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Methotrexate-associated lymphoproliferative disorder of the heart. 甲氨蝶呤相关性心脏淋巴组织增生性疾病。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae091
Toshiyuki Sumi, Keito Suzuki, Kotomi Arioka, Hirofumi Chiba
{"title":"Methotrexate-associated lymphoproliferative disorder of the heart.","authors":"Toshiyuki Sumi, Keito Suzuki, Kotomi Arioka, Hirofumi Chiba","doi":"10.1093/jjco/hyae091","DOIUrl":"10.1093/jjco/hyae091","url":null,"abstract":"","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141633523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Geriatric nutritional risk index as a predictor for surgical site infection in malignant musculoskeletal tumours of the trunk. 预测躯干恶性肌肉骨骼肿瘤手术部位感染的老年营养风险指数。
IF 1.9 4区 医学 Q3 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1093/jjco/hyae095
Sakura Shiraishi, Toshifumi Fujiwara, Akira Nabeshima, Keiichiro Iida, Makoto Endo, Yoshihiro Matsumoto, Yoshinao Oda, Yasuharu Nakashima

Background and objective: Surgical site infection (SSI) is common in surgery for malignant musculoskeletal tumours, specifically those arising from the trunk. In this study, we investigated the risk factors for SSI after resection of musculoskeletal tumours of the trunk.

Methods: This retrospective observational study included 125 patients (72 males, 53 females) with musculoskeletal tumours of the trunk in our hospital from 1 April 2008 to 31 August 2023. The incidence of SSI and its risk factors were investigated.

Results: SSI was observed in 26% (32/125), and the median time to SSI was 22 days. On multivariate analysis, the following were identified as risk factors for SSI: tumours arising caudal to Jacoby's line (hazard ratio [HR] 4.04; P = .0107), soft tissue reconstruction (HR 3.43; P = .0131), and low Geriatric Nutritional Risk Index (GNRI) (HR 0.96; P = .0304). Patients were classified into two risk categories based on GNRI scores: the risk group (GNRI ≤98) and no risk group (>98). The risk group showed a significantly lower overall noninfection survival rate (P = .023).

Conclusion: Tumours arising caudal to Jacoby line, soft tissue reconstruction, and lower GNRI were risk factors for SSI. Preoperative and postoperative nutritional interventions should be considered to improve GNRI.

背景和目的:手术部位感染(SSI)是恶性肌肉骨骼肿瘤手术中的常见病,尤其是躯干肿瘤。在这项研究中,我们调查了躯干肌肉骨骼肿瘤切除术后发生 SSI 的风险因素:这项回顾性观察研究纳入了我院 2008 年 4 月 1 日至 2023 年 8 月 31 日期间 125 例躯干肌肉骨骼肿瘤患者(男 72 例,女 53 例)。研究调查了 SSI 的发生率及其风险因素:结果:26%(32/125)的患者出现 SSI,SSI 的中位时间为 22 天。经多变量分析,以下因素被确定为SSI的风险因素:肿瘤位于雅各比线尾部(危险比[HR]4.04;P = .0107)、软组织重建(HR 3.43;P = .0131)和老年营养风险指数(GNRI)低(HR 0.96;P = .0304)。根据 GNRI 分数将患者分为两个风险类别:风险组(GNRI ≤98)和无风险组(>98)。风险组的非感染总生存率明显较低(P = .023):结论:雅各比线尾部的肿瘤、软组织重建和较低的 GNRI 是 SSI 的风险因素。应考虑进行术前和术后营养干预,以提高 GNRI。
{"title":"Geriatric nutritional risk index as a predictor for surgical site infection in malignant musculoskeletal tumours of the trunk.","authors":"Sakura Shiraishi, Toshifumi Fujiwara, Akira Nabeshima, Keiichiro Iida, Makoto Endo, Yoshihiro Matsumoto, Yoshinao Oda, Yasuharu Nakashima","doi":"10.1093/jjco/hyae095","DOIUrl":"10.1093/jjco/hyae095","url":null,"abstract":"<p><strong>Background and objective: </strong>Surgical site infection (SSI) is common in surgery for malignant musculoskeletal tumours, specifically those arising from the trunk. In this study, we investigated the risk factors for SSI after resection of musculoskeletal tumours of the trunk.</p><p><strong>Methods: </strong>This retrospective observational study included 125 patients (72 males, 53 females) with musculoskeletal tumours of the trunk in our hospital from 1 April 2008 to 31 August 2023. The incidence of SSI and its risk factors were investigated.</p><p><strong>Results: </strong>SSI was observed in 26% (32/125), and the median time to SSI was 22 days. On multivariate analysis, the following were identified as risk factors for SSI: tumours arising caudal to Jacoby's line (hazard ratio [HR] 4.04; P = .0107), soft tissue reconstruction (HR 3.43; P = .0131), and low Geriatric Nutritional Risk Index (GNRI) (HR 0.96; P = .0304). Patients were classified into two risk categories based on GNRI scores: the risk group (GNRI ≤98) and no risk group (>98). The risk group showed a significantly lower overall noninfection survival rate (P = .023).</p><p><strong>Conclusion: </strong>Tumours arising caudal to Jacoby line, soft tissue reconstruction, and lower GNRI were risk factors for SSI. Preoperative and postoperative nutritional interventions should be considered to improve GNRI.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141748169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Japanese journal of clinical oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1